Rheumatic fever primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| (7 intermediate revisions by 4 users not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Effective measures for the primary prevention of rheumatic fever include reducing exposure to [[ | Effective measures for the primary [[prevention]] of rheumatic fever include reducing exposure to [[Group A beta-hemolytic streptococci]] and [[antibiotic]] [[prophylaxis]] for [[streptococcal pharyngitis]]. [[Intramuscular]] [[benzathine penicillin G]] and oral [[penicillin V]] are the recommended [[antibiotics]] in treatment of [[group A streptococcal infection]] in absence of [[penicillin allergy]]. | ||
==Primary Prevention== | ==Primary Prevention== | ||
Effective measures for the primary prevention of rheumatic fever include reducing exposure to [[ | Effective measures for the primary [[prevention]] of rheumatic fever include reducing exposure to [[Group A beta-hemolytic streptococci]], which requires dramatic improvements in housing, [[hygiene]] infrastructure and access to health care for individuals in the developing countries.<ref name="pmid15927077">{{cite journal| author=Robertson KA, Volmink JA, Mayosi BM| title=Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. | journal=BMC Cardiovasc Disord | year= 2005 | volume= 5 | issue= 1 | pages= 11 | pmid=15927077 | doi=10.1186/1471-2261-5-11 | pmc=PMC1164408 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15927077 }} </ref> Most [[streptococcal pharyngitis]], when treated with appropriate [[antibiotics]], prevents acute rheumatic fever.<ref name="pmid15415234">{{cite journal| author=DENNY FW, WANNAMAKER LW, BRINK WR, RAMMELKAMP CH, CUSTER EA| title=Prevention of rheumatic fever; treatment of the preceding streptococcic infection. | journal=J Am Med Assoc | year= 1950 | volume= 143 | issue= 2 | pages= 151-3 | pmid=15415234 | doi= | pmc= | url= }} </ref> Unfortunately, at least one third of episodes of acute rheumatic fever result from unapparent [[streptococcal infections]].<ref name="pmid1945592">{{cite journal| author=Dajani AS| title=Current status of nonsuppurative complications of group A streptococci. | journal=Pediatr Infect Dis J | year= 1991 | volume= 10 | issue= 10 Suppl | pages= S25-7 | pmid=1945592 | doi= | pmc= | url= }} </ref> In addition, some [[symptomatic]] [[patients]] do not seek [[medical]] care; in these instances, rheumatic fever is not preventable. | ||
===Antimicrobial Regimens=== | ===Antimicrobial Regimens=== | ||
*Primary prevention of rheumatic fever via antimicrobial regimens:<ref name="pmid19246689">{{cite journal| author=Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST et al.| title=Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. | journal=Circulation | year= 2009 | volume= 119 | issue= 11 | pages= 1541-51 | pmid=19246689 | doi=10.1161/CIRCULATIONAHA.109.191959 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19246689 }} </ref> | *Primary [[prevention]] of rheumatic fever via [[antimicrobial]] regimens:<ref name="pmid19246689">{{cite journal| author=Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST et al.| title=Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. | journal=Circulation | year= 2009 | volume= 119 | issue= 11 | pages= 1541-51 | pmid=19246689 | doi=10.1161/CIRCULATIONAHA.109.191959 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19246689 }} </ref> | ||
:* Preferred regimen (1): [[Penicillin V]] 500 mg PO q6-8h for 10 days | :* Preferred regimen (1): [[Penicillin V]] 500 mg PO q6-8h for 10 days | ||
:* Preferred regimen (2): [[Amoxicillin]] 50 mg/kg PO qd for 10 days (maximum dose 1 g) | :* Preferred regimen (2): [[Amoxicillin]] 50 mg/kg PO qd for 10 days (maximum dose 1 g) | ||
| Line 24: | Line 24: | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
Latest revision as of 00:00, 30 July 2020
|
Rheumatic fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Rheumatic fever primary prevention On the Web |
|
American Roentgen Ray Society Images of Rheumatic fever primary prevention |
|
Risk calculators and risk factors for Rheumatic fever primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Lance Christiansen, D.O.; Associate Editor(s)-in-Chief: Varun Kumar, M.B.B.S. [2]; Cafer Zorkun, M.D., Ph.D. [3]; Anthony Gallo, B.S. [4]
Overview
Effective measures for the primary prevention of rheumatic fever include reducing exposure to Group A beta-hemolytic streptococci and antibiotic prophylaxis for streptococcal pharyngitis. Intramuscular benzathine penicillin G and oral penicillin V are the recommended antibiotics in treatment of group A streptococcal infection in absence of penicillin allergy.
Primary Prevention
Effective measures for the primary prevention of rheumatic fever include reducing exposure to Group A beta-hemolytic streptococci, which requires dramatic improvements in housing, hygiene infrastructure and access to health care for individuals in the developing countries.[1] Most streptococcal pharyngitis, when treated with appropriate antibiotics, prevents acute rheumatic fever.[2] Unfortunately, at least one third of episodes of acute rheumatic fever result from unapparent streptococcal infections.[3] In addition, some symptomatic patients do not seek medical care; in these instances, rheumatic fever is not preventable.
Antimicrobial Regimens
- Primary prevention of rheumatic fever via antimicrobial regimens:[4]
- Preferred regimen (1): Penicillin V 500 mg PO q6-8h for 10 days
- Preferred regimen (2): Amoxicillin 50 mg/kg PO qd for 10 days (maximum dose 1 g)
- Preferred regimen (3): Penicillin G 0.6 MU IM single dose (≤27 kg / ≤60 lb); 1.2 MU IM single dose (>27 kg / >60 lb)
- Alternative regimen (1): Cephalexin 500 mg PO bid for 10 days
- Alternative regimen (2): Cefadroxil 1 g PO qd for 10 days
- Alternative regimen (3): Clindamycin 20 mg/kg/day PO tid for 10 days (maximum dose 1.8 g/day)
- Alternative regimen (4): Azithromycin 12 mg/kg PO qd for 5 days (maximum dose 500 mg/day)
- Alternative regimen (5): Clarithromycin 15 mg/kg/day PO bid for 10 days (maximum 500 mg/day)
References
- ↑ Robertson KA, Volmink JA, Mayosi BM (2005). "Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis". BMC Cardiovasc Disord. 5 (1): 11. doi:10.1186/1471-2261-5-11. PMC 1164408. PMID 15927077.
- ↑ DENNY FW, WANNAMAKER LW, BRINK WR, RAMMELKAMP CH, CUSTER EA (1950). "Prevention of rheumatic fever; treatment of the preceding streptococcic infection". J Am Med Assoc. 143 (2): 151–3. PMID 15415234.
- ↑ Dajani AS (1991). "Current status of nonsuppurative complications of group A streptococci". Pediatr Infect Dis J. 10 (10 Suppl): S25–7. PMID 1945592.
- ↑ Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST; et al. (2009). "Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics". Circulation. 119 (11): 1541–51. doi:10.1161/CIRCULATIONAHA.109.191959. PMID 19246689.